Smartlens

Smartlens operates in ophthalmic medical devices and digital eye health, with a focus on glaucoma and anterior segment conditions. Its differentiator is the attempt to combine continuous or diurnal intraocular pressure monitoring through miLens with analytics, AI-enabled eye imaging, and personalized micro-dose drug delivery. The stated technology set includes a microfluidic sensing contact lens, miLens IQ analytics, an AI-powered remote eye examination and imaging platform, and THERx IQ automated drug delivery. Smartlens reports first-in-human work, U.S. pilot trials, and initiated U.S. pivotal trials, placing miLens in clinical development rather than establishing broad commercial adoption. The company’s competitive position will depend on clinical evidence, regulatory progress, usability, and whether the connected monitoring-and-treatment model can be adopted in routine eye care.

Smartlens’s disclosed trajectory centers on moving miLens from development into more advanced clinical and regulatory work while building a broader ophthalmic care platform. The clearest financial inflection point is the $5.2 million Seed financing announced on Oct 29, 2025, with Ambit Health Ventures, Graphene Ventures, Boutique Venture Partners, Harvard Business School Alumni Angels GNY, and a group of eyecare providers among the named participants. That financing was associated with advancing miLens toward FDA clearance and launch. Product development extends beyond the sensor: miLens IQ supplies analytics, an AI-enabled imaging and remote examination platform supports assessment, and THERx IQ targets personalized drug delivery. The financial signals also list a Series A round without an amount or date, so it cannot be treated as a confirmed completed financing milestone. The next meaningful indicators of growth would be clinical results, regulatory decisions, commercialization evidence, and clarity on whether the Series A entry represents a completed round.